Adagene Management

Management criteria checks 2/4

Adagene's CEO is Peizhi Luo, appointed in Nov 2011, has a tenure of 14.67 years. directly owns 0.18% of the company’s shares, worth $471.27K. The average tenure of the management team and the board of directors is 7.8 years and 4.7 years respectively.

Key information

Peizhi Luo

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	14.7yrs
CEO ownership	0.2%
Management average tenure	7.8yrs
Board average tenure	4.7yrs

Recent management updates

Recent updates

Analysis Article • Oct 10

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Adagene Inc. ( NASDAQ:ADAG ) shareholders would be excited to see that the share price has had a great month, posting a...

Analysis Article • Oct 05

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

The latest analyst coverage could presage a bad day for Adagene Inc. ( NASDAQ:ADAG ), with the analysts making...

Seeking Alpha • Aug 30

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Adagene ADR press release (NASDAQ:ADAG): 1H GAAP EPS of -$0.87 misses by $0.45. Revenue of $3.93M (+189.0% Y/Y) misses by $9.82M. Financial Outlook of 2023. ADG116 phase 2a proof-of-concept data from combination dose expansion cohorts. ADG126 phase 2a proof-of-concept data from combination dose expansion cohorts Establish registration path and strategy (e.g., recommended phase 2 dose, indication and design) for phase 2/3 pivotal trial of anti-CTLA-4 in combination with anti-PD-1 therapy in targeted tumors Initiate patient dosing in ADG206 phase 1 trial Submit IND or equivalent for ADG153, and initiate phase 1 trial Results from IIT combination studies of ADG106 Additional collaborations and/or technology licensing agreements

Seeking Alpha • Jun 29

Micro-cap Adagene surges after hours on $10M share buyback

Adagene (NASDAQ:ADAG) on Wednesday authorized a share buyback of up to $10M of its U.S.-listed shares. The micro-cap company's stock surged ~30% to $2.72 in aftermarket trading. ADAG said it expects to use its existing funds to fund repurchases made under the share buyback program. ADAG stock has tumbled nearly 89% from its IPO price of $19.

CEO

Peizhi Luo (60 yo)

14.7yrs

Tenure

Dr. Dr. Peter P. Luo (Peizhi), Ph D., also known as Peizhi, is Founder & Chief Executive Officer and Director of Adagene (Suzhou) Limited. and serves as its Chief Executive Officer since November 2011 and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Peter P. Luo	Co- Founder	14.7yrs	no data	0.18% $ 471.3k
Man Kin Tam	CFO & Director	6.8yrs	no data	0.14% $ 367.5k
Ling Zhou	Executive Director & Head of Human Resources	6.8yrs	no data	0.0036% $ 9.3k
Qinghai Zhao	Chief Manufacturing Officer	5.8yrs	no data	0.16% $ 410.4k
Mickael Chane-Du	Chief Strategy Officer	1.5yrs	no data	0.34% $ 881.0k
Chunfang Gu	Executive Director of Finance	no data	no data	0.0085% $ 22.2k
Yan Li	Senior Vice President of Bioinformatics & Information Technology	14.7yrs	no data	no data
Xiaohong She	Senior VP & Head of Clinical Operations	14.7yrs	no data	0.068% $ 176.6k
Guizhong Liu	Senior Vice President of Early Drug Discovery	10.8yrs	no data	no data
Alexander Goergen	VP & Head of Business Development	8.8yrs	no data	no data
Jiping Zha	Executive Vice President of Clinical Development	4.8yrs	no data	no data
Songmao Zheng	Senior VP of Clinical Pharmacology & Quantitative Sciences	no data	no data	no data

7.8yrs

Average Tenure

55yo

Average Age

Experienced Management: ADAG's management team is seasoned and experienced (7.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Peter P. Luo	Co- Founder	8.4yrs	no data	0.18% $ 471.3k
Man Kin Tam	CFO & Director	5.4yrs	no data	0.14% $ 367.5k
Li Zhu	Independent Director	2.9yrs	no data	0.032% $ 82.7k
Steven Alan Fischkoff	Member of Scientific & Strategic Advisory Board	4.9yrs	no data	no data
Robert Jay Spiegel	Member Scientific and Strategic Advisory Board	4.9yrs	no data	no data
Cuong Viet Do	Independent Director	3.7yrs	no data	0.048% $ 126.1k
Ulf Grawunder	Independent Director	2.3yrs	no data	0.054% $ 141.9k
David R. Gandara	Member Scientific & Strategic Advisory Board	4.5yrs	no data	no data
Heinz-Josef Lenz	Member of Scientific & Strategic Advisory Board	2.3yrs	no data	no data
Aurelien Marabelle	Member of Scientific & Strategic Advisory Board	3.3yrs	no data	no data
Yiu Leung Cheung	Independent Director	5.4yrs	no data	0.032% $ 82.7k
Stanley Frankel	Member Scientific & Strategic Advisory Board	4.9yrs	no data	no data

4.7yrs

Average Tenure

66yo

Average Age

Experienced Board: ADAG's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/12 02:37
End of Day Share Price	2026/07/10 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Adagene Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ziyi Chen	Goldman Sachs
Paul Jeng	Guggenheim Securities, LLC
Yu He	H.C. Wainwright & Co.

Adagene Management

Management criteria checks 2/4

Key information

Recent management updates

Adagene Inc. Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

Adagene Inc. Announces Board Changes

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Price target increased by 18% to US$9.40

Adagene Inc. Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

Adagene Inc. has completed a Follow-on Equity Offering in the amount of $69.9975 million.

Adagene Inc. has filed a Follow-on Equity Offering.

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Adagene Inc. Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA®? (Pembrolizumab) in Microsatellite Stable Colorectal Cancer

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B Meeting with FDA

Adagene Inc. announced that it expects to receive $25 million in funding from Sanofi Foreign Participations B.V.

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA®? (Pembrolizumab) in Colorectal Cancer At the American Society of Clinical Oncology Annual Meeting

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

Adagene Inc. Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.83 loss per share (vs US$1.85 loss in FY 2022)

Adagene Inc. Announces Board Changes

New minor risk - Financial data availability

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody

New major risk - Share price stability

Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium

Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.16

Full year 2022 earnings released: US$1.85 loss per share (vs US$1.83 loss in FY 2021)

Price target decreased by 9.4% to US$12.53

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-Ctla-4 Safebody® Adg126 Up to 10 Mg/Kg with Repeat Cycles in Combination with Anti-Pd-1 Therapy from Dose Escalation Portion of Phase 1B/2 Trial

Price target increased to US$13.82

Price target decreased to US$10.78

Price target decreased to US$12.71

High number of new and inexperienced directors

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Consensus forecasts updated

Price target increased to US$27.92

First half 2022 earnings released: US$1.09 loss per share (vs US$1.02 loss in 1H 2021)

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Micro-cap Adagene surges after hours on $10M share buyback

High number of new and inexperienced directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$25.69

Director Yu Miao has left the company

Adagene Inc. has completed an IPO in the amount of $139.726 million.

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources